To assess the association of testosterone replacement therapy (TRT) with thromboembolism, cardiovascular disease (stroke, coronary artery disease and heart failure) and obstructive sleep apnoea (OSA).
Introduction
Testosterone levels decline with age; as many as 25% of middle-aged and older men have androgen levels below reference ranges for young men [1] . Given that symptoms of aging, such as decreased muscle mass, poor libido, erectile dysfunction, osteoporosis and increased adipose tissue are also observed in young men with androgen insufficiency, there has been interest in testosterone replacement therapy (TRT) to alleviate these symptoms in middle-aged men who do not have definitive pituitary or testicular disease [2, 3] . Despite mixed evidence of its efficacy, a burgeoning industry in TRT has developed, with total sales growing from only $18 m per year in 1988 to over $1.6 billion in 2011 [4] .
The increased use of TRT has occurred despite controversy about possible medical side effects. These include an extensive but somewhat inconclusive series of both randomized prospective trials and population-based studies, some suggesting the possibility of increased cardiovascular and thromboembolic risk [5] [6] [7] [8] . The relationship between obstructive sleep apnoea (OSA) and TRT is less well studied, although many have postulated a link [9] . This has mainly been anecdotal, or in the context of small, randomized controlled trials, several of which have used supraphysiological testosterone levels [10, 11] . Liu et al. [12] , for example, performed a randomized trial in 17 men in a community setting. Using a crossover design with polysomnography and metabolic measurements, they showed that i.m. testosterone administration reduced total time sleeping time, increased the duration of nocturnal hypoxaemia and disrupted breathing during sleep [12] . Other studies have shown the opposite: men with low testosterone levels may have reduced sleep quality, which can potentially be corrected with replacement [13] . As a result of this possible association, the 2010 Endocrine Society guidelines mention existing OSA as a relative contraindication to TRT [14] . Ultimately, however, the epidemiological relationship between TRT and OSA has not been evaluated within a large epidemiological study.
Further complicating the study of TRT, 2003 Institute of Medicine guidelines de-emphasize experimentation on healthy men for lifestyle purposes or when existing safe and effective therapies (e.g. bisphosphonates for osteoporosis or phosphodiesterase-5 inhibitors for erectile dysfunction) are widely used [15] . As a consequence, clinical trials of TRT have been mainly limited to comorbid and older patient populations with diseases treatable with TRT. While retrospective observational studies could gain insight into younger, healthier populations, many previous studies have been in Veterans Affairs or Medicare populations, which consist mainly of older men [6, 16] . Additionally, in March 2015, US Food and Drug Administration warnings on testosterone formulations (http://www.fda.gov/Drugs/DrugSafe ty/ucm436259.html) were changed to include the risk of stroke and heart disease, which may further limit opportunities to study TRT in healthy men.
Given limited data on TRT in middle-aged, healthy men, especially with regard to OSA, we designed a retrospective study to assess rates of adverse events for such men using a large national database of service men on active duty and retired US service members and their dependents. Specifically, we sought to compare the occurrence of thromboembolic complications, cardiovascular events and OSA between a cohort of middle-aged men using TRT for low testosterone levels and a cohort of age-and comorbidity-matched controls. We hypothesized that TRT use would be associated with cardiovascular disease, thromboembolic disease and OSA.
Materials and Methods
The present study had a retrospective matched cohort design using a large military database. The study relies on data extracted from the Military Health System Data Repository, which includes inpatient and outpatient coding and pharmacy information for patients covered by the TRICARE â benefit. TRICARE is the healthcare programme for active members of the US Uniformed Services, retirees, and their family members, and is administrated by the Defence Health Agency. The TRICARE database includes all insurance claims through this benefit, consisting of both routine preventative care, hospitalizations and prescription drug benefits.
To evaluate the risk of adverse effects of TRT, we identified 36 882 men who received at least one dose of TRT between January 2006 and December 2010. We selected men according to the following inclusion criteria: continuous use of TRT (n = 28 344); 180-day washout period, determined as start of TRT after 1 July 2006 (n = 22 045); and no history of thromboembolic, cardiovascular events or OSA (n = 17 712). Participants had to have been enrolled in TRICARE for at least 1 year (n = 13 401) and to have had a diagnosis of low testosterone levels (n = 4 826). Finally, we included only men aged 40-64 years (n = 4 061) and excluded those with a primary hypercoagulable state (n = 4 060) and those who had used oral testosterone, which is not currently approved for TRT in the USA (n = 4 028). Matched controls from the TRICARE database were identified using the same inclusion criteria, minus the use of TRT, as described in the Statistical Analysis Section, below.
Covariates
For each participant, age, race, marital status, region of residence, alcohol and tobacco consumption, and tobacco history were obtained from the TRICARE database. As a proxy for socio-economic status, we used military rank (enlisted: junior or senior, officer: junior, senior or warrant, cadet), a method previously used to infer social status in military research [17] [18] [19] [20] . Additionally, comorbidities were extracted and used in the matching of TRT users and controls, as described below.
Study Endpoints
The primary endpoints of the present study were time to first diagnosis of thromboembolic events, cardiovascular events (analysed both in aggregate and separately as coronary artery disease [CAD] , congestive heart failure [CHF] and stroke), as well as OSA. We relied on diagnosis codes from inpatient or physician office visits corresponding to thromboembolic events, cardiovascular events or OSA (See Table S2 for list of diagnosis and procedure codes). To ascertain the effect of TRT on these side effects we compared event-free survival for endpoints as a function of time and calculated the 2-year absolute risk.
Statistical Analysis
Once the TRT cohort was identified, we performed a three-stage matching technique to identify a control cohort which would minimize bias [21] . First, all male beneficiaries were selected to match to the case cohort based on their birth year to generate the artificial 'twin pair'. Second, for each twin pair, we assigned the first date 
Final matched controls n=3422
Final cohort n=6844 of the case's TRT prescription date to their matched pair as the starting point to create the control pool (using only controls with continuous enrolment in TRICARE for 12 months prior to the assigned start date). Baseline comorbidity conditions and risk factors were assessed for eligible matched pairs. Finally, one-to-one matching without replacement based on race, baseline conditions, including low testosterone and risk factors (Table 1 ) was used to generate the final case and control cohort. After matching was completed, unweighted Kaplan-Meier curves were used to compare the adverse event-free survival between cases and controls. We used a log-rank test to evaluate significance. We then calculated 2-year risk of adverse events with 95% CIs.
All statistical testing was two-sided, with a level of significance set at 0.05. Analyses were performed using SAS, version 9.3 (SAS Institute, Cary, NC, USA 
Results

Pre-matching
Overall, we identified 3 422 men who met the inclusion criteria and who received TRT between 2006 and 2010. The mean (range) age of this cohort was 52 (40-64) years. The majority were white (70.46%), married (93.4%) and geographically located in the southern USA (69.12%). Most were ranked as senior enlisted (72.2%). The most common comorbidities were chronic pulmonary disease (19.64%), diabetes (26.64%), obesity (20.16%), hypertension (58.17%) and hyperlipidaemia (62.29%). The baseline characteristics of the study cohort are summarized in Table 1 . The majority of men (~80%) used topical testosterone formulations, with the remainder using a variety of injectable formulations (Table S1 ).
Post-matching
After matching, case and control groups included 3 422 twin pairs. Cases and controls were well matched on demographics and had 1:1 concordance with respect to listed comorbidities.
Kaplan-Meier Comparison
Kaplan-Meier curves show the event-free survival for primary endpoints including diagnosis of thromboembolic and cardiovascular events, and diagnosis of OSA in Fig. 2 . Compared with controls, men who received TRT had longer cardiovascular event-free survival (P = 0.009) but a greater risk of OSA (P < 0.001). The longer cardiovascular event-free survival was predominantly driven by a significantly lower risk of CAD among testosterone users (P = 0.008). Risk of stroke and CHF was not significantly different. There was also no statistically significant difference in rates of thromboembolism (Fig. 3) .
Absolute Risk of Adverse Events
The absolute 2-year risk of thromboembolic events was 2.0% (95% CI: 1.5-2.7) in the TRT cohort vs 1.4% (95% CI: 1.0-2.0) in the control group. The 2-year absolute risk of cardiovascular events was 8.2% (95% CI: 7.1-9.5) for TRT users vs 10.5% (95% CI: 9.3-11.8) for controls. When subdividing into CHF, stroke and CAD, CAD was the only endpoint with significantly lower risk among TRT users. By contrast, the risk of OSA was higher among TRT users, with a 2-year absolute risk of 16.5% (95% CI: 15.1-18.1) among Table 2) . Comparison of the frequency of study endpoints, stratified by TRT formulations, is shown in Table S1 .
Discussion
In this large, matched cohort study comparing 3 422 former and active duty military service members receiving TRT with TRT Users Controls P=0.0082
TRT Users Controls
P=0.1844
TRT Users Controls age-and comorbidity-matched controls, there was no significant difference in event-free survival for thromboembolic events. A small but statistically significant decrease in cardiovascular risk was seen in TRT users, predominantly driven by lower risk of CAD. Finally, we found that men using TRT had a greater risk of developing OSA. While previously demonstrated in small prospective studies, this association has not previously been shown in a large national study such as this.
The strengths of the present study lie in the use of a large, geographically and ethnically diverse dataset to assess the risk of developing medical side effects in a men using TRT. The matching process is another strength; given the large size of this database (9.5 million beneficiaries), we were able to obtain twin pairs with exact matching of comorbidities, birth year and rank.
The present study is one among a long series of studies, at times conflicting, attempting to use large datasets to evaluate the impact of TRT on cardiovascular and thromboembolic disease. Notably, we did not observe a higher thrombotic risk in TRT users as was recently shown in published populationbased data from the UK [8] . Similarly, we found no increase in cardiovascular side effects previously demonstrated in studies of more elderly and mobility-impaired men using TRT [5, 6] . Overall, our study population was younger (mean age 52 years) and healthier than that of many previous studies on cardiovascular risk in TRT users, possibly suggesting that, among more healthy young men, the risk of cardiovascular side effects may not be as high as once feared. Further, recently published prospective data suggest the same [7] and our results are consistent with these.
Our finding of increased risk of OSA among TRT users is noteworthy. This link has long been suspected and there are a variety of possible physiological mechanisms. These include morphological and neuromuscular changes to the airways, changes in metabolic requirements, as well as changes to the physiological response to hypoxaemia and hypercapnia. Androgens do play some role in the development of the airway [12] . Additionally, dilatation of the upper airway depends on contraction of certain dilator muscles (e.g. the genioglossus), which is mediated by serotoninergic and noradrenergic neurons travelling in parallel [22, 23] . Both may be affected by age and androgen levels. Alternative explanations concern the possibility of higher metabolic requirements with elevated testosterone levels, which may result in higher oxygen consumption which, in turn, could lead to hypoxia [9] . Other plausible explanations involve a role for androgens in the neural response pathways to hypoxia and hypercapnia [24] . If fluctuating androgen levels affect the ventilatory response to hypercapnia, this could explain the higher rates of OSA in men receiving TRT [11, 12] . Although previous small studies and case series have explored this, the present study is the first large, populationbased study to observe an elevated risk of OSA among TRT users compared with controls.
While the study was not designed as a head-to-head comparison of TRT formulations, we observed a borderline significant trend towards higher than expected frequency of OSA in certain injectable TRT formulations (Table S1 ). Given the potential role for fluctuating androgen levels in OSA, this finding is noteworthy and may be a consequence of less consistent androgen levels with some injectable agents. Nevertheless, this was a secondary, exploratory analysis involving multiple comparisons, thus the results should not be viewed as a definitive verdict regarding types of TRT.
Other limitations of the present study include the possibility of unmeasured confounders. These include patient characteristics not captured by diagnostic codes, e.g. the specific aetiology of low testosterone levels (low testosterone from pituitary sources, orchiectomy, primary testicular failure, etc.). In the case of obesity, an important confounder for OSA, we were able to match TRT users and controls based on diagnostic codes for obesity; however, our data did not include specific body mass index (BMI) values. If the specific values of BMI among obese and non-obese TRT users differed systematically from non-TRT users this could have introduced bias.
Because the data source consisted of International Classification of Diseases diagnostic and procedural codes Additionally, despite our geographically diverse population, service members, retirees and their dependents may differ from the civilian population and so limit the generalizability of our data.
Another limitation includes the potential for 'healthy man' bias. Although we attempted to match by diagnostic claims there may be more subtle aspects of general health which may confound these findings, as well as laboratory values and physical characteristics, such as BMI, which are not captured by diagnostic codes, cannot be included in the matching procedure, and which therefore may result in more healthy men being prescribed TRT. This could explain the lower cardiovascular risks in men using TRT. Lack of data on testosterone levels (both pre-and post-treatment), no information on specific symptoms of hypogonadism, and lack of blinding and randomized design are further limitations. For example, because clinicians are probably aware of patients' use of TRT they may be more likely to screen for adverse events such as OSA, leading to artificially inflated rates in the exposed cohort compared with the controls. Finally, while an integrated electronic medical record used at military facilities may increase charge capture, miscoding errors are possible as is the case in any large claims-based datasets [25] .
While the findings of no increased risk of thromboembolism and cardiovascular disease endpoints are reassuring, the finding of an increased risk of OSA among men using TRT is novel in the context of a large population-based study. Although current Endocrine Society guidelines mention untreated OSA as a relative contraindication for TRT [14, 26] , given these results and the significant downstream effects of OSA on overall health, physicians should consider including OSA in discussions about the potential the risks and benefits of TRT.
